Interim report January – March 2024
First quarter in brief · Net sales amounted to 17.8 million SEK (16.1), which means a sales growth of 10 percent. · Operating profit amounted to 2.7 million SEK (-2), corresponding to an operating margin of 15 percent (-13). · Net profit for the period amounted to 3.4 million SEK (-2,2). · Earnings per share amounted to 0.08 SEK (-0.05). Significant events during the first quarter In February 2024, the extraordinary general meeting decided to establish a long-term incentive program. SyntheticMR has received FDA 510K approval for SyMRI 3D. Significant events